Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma

被引:22
作者
Caruso, James P. [1 ]
Cohen-Inbar, Or [1 ,7 ]
Bilsky, Mark H. [3 ,4 ]
Gerszten, Peter C. [5 ,6 ]
Sheehan, Jason P. [1 ,2 ]
机构
[1] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22908 USA
[2] Univ Virginia Hlth Syst, Dept Radiat Oncol, Charlottesville, VA 22908 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10021 USA
[4] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA
[5] Univ Pittsburgh, Sch Med, UPMC Hlth Syst, Dept Neurol Surg, Pittsburgh, PA USA
[6] Univ Pittsburgh, Sch Med, UPMC Hlth Syst, Dept Radiat Oncol, Pittsburgh, PA USA
[7] Technion Israel Inst Technol, Mol Immunol & Tumor Immunotherapy Lab, Haifa, Israel
关键词
metastatic spinal melanoma; stereotactic radiosurgery; separation surgery; immunotherapy; review; TUMOR-INFILTRATING LYMPHOCYTES; BRAIN METASTASES; HIGH-RISK; INTERFERON-ALPHA; CTLA-4; BLOCKADE; DOSE INTERLEUKIN-2; BODY RADIOTHERAPY; SAFETY; CANCER; THERAPY;
D O I
10.3171/2014.11.FOCUS14716
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The management of metastatic spinal melanoma involves maximizing local control, preventing recurrence, and minimizing treatment-associated toxicity and spinal cord damage. Additionally, therapeutic measures should promote mechanical stability, facilitate rehabilitation, and promote quality of life. These objectives prove difficult to achieve given melanoma's elusive nature, radioresistant and chemoresistant histology, vascular character, and tendency for rapid and early metastasis. Different therapeutic modalities exist for metastatic spinal melanoma treatment, including resection (definitive, debulking, or stabilization procedures), stereotactic radiosurgery, and immunotherapeutic techniques, but no single treatment modality has proven fully effective. The authors present a conceptual overview and critique of these techniques, assessing their effectiveness, separately and combined, in the treatment of metastatic spinal melanoma. They provide an up-to-date guide for multidisciplinary treatment strategies. Protocols that incorporate specific, goal-defined surgery, immunotherapy, and stereotactic radiosurgery would be beneficial in efforts to maximize local control and minimize toxicity.
引用
收藏
页数:10
相关论文
共 94 条
[1]   Stereotactic Body Radiation Therapy in Spinal Metastases [J].
Ahmed, Kamran A. ;
Stauder, Michael C. ;
Miller, Robert C. ;
Bauer, Heather J. ;
Rose, Peter S. ;
Olivier, Kenneth R. ;
Brown, Paul D. ;
Brinkmann, Debra H. ;
Laack, Nadia N. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05) :E803-E809
[2]  
[Anonymous], PRINCIPLES PRACTICE
[3]  
[Anonymous], IMMUNOLOGY
[4]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[5]   Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion [J].
Baker, PK ;
Pettitt, AR ;
Slupsky, JR ;
Chen, HJ ;
Glenn, MA ;
Zuzel, M ;
Cawley, JC .
BLOOD, 2002, 100 (02) :647-653
[6]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[7]   Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1 mm) with vertical growth phase [J].
Bedrosian, I ;
Faries, MB ;
Guerry, D ;
Elenitsas, R ;
Schuchter, L ;
Mick, R ;
Spitz, FR ;
Bucky, LP ;
Alavi, A ;
Elder, DE ;
Fraker, DL ;
Czerniecki, BJ .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (04) :262-267
[8]   Interferons α and β as immune regulators -: A new look [J].
Biron, CA .
IMMUNITY, 2001, 14 (06) :661-664
[9]   Vemurafenib: the first drug approved for BRAF-mutant cancer [J].
Bollag, Gideon ;
Tsai, James ;
Zhang, Jiazhong ;
Zhang, Chao ;
Ibrahim, Prabha ;
Nolop, Keith ;
Hirth, Peter .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) :873-886
[10]   Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].
Bollag, Gideon ;
Hirth, Peter ;
Tsai, James ;
Zhang, Jiazhong ;
Ibrahim, Prabha N. ;
Cho, Hanna ;
Spevak, Wayne ;
Zhang, Chao ;
Zhang, Ying ;
Habets, Gaston ;
Burton, ElizabethA. ;
Wong, Bernice ;
Tsang, Garson ;
West, Brian L. ;
Powell, Ben ;
Shellooe, Rafe ;
Marimuthu, Adhirai ;
Nguyen, Hoa ;
Zhang, Kam Y. J. ;
Artis, Dean R. ;
Schlessinger, Joseph ;
Su, Fei ;
Higgins, Brian ;
Iyer, Raman ;
D'Andrea, Kurt ;
Koehler, Astrid ;
Stumm, Michael ;
Lin, Paul S. ;
Lee, Richard J. ;
Grippo, Joseph ;
Puzanov, Igor ;
Kim, Kevin B. ;
Ribas, Antoni ;
McArthur, Grant A. ;
Sosman, Jeffrey A. ;
Chapman, Paul B. ;
Flaherty, Keith T. ;
Xu, Xiaowei ;
Nathanson, Katherine L. ;
Nolop, Keith .
NATURE, 2010, 467 (7315) :596-599